Abstract
Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Volume: 8 Issue: 1
Author(s): D. Digiuseppe and C. Feliciani
Affiliation:
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Abstract: Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Export Options
About this article
Cite this article as:
Digiuseppe D. and Feliciani C., Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (1) . https://dx.doi.org/10.2174/187152309787580766
DOI https://dx.doi.org/10.2174/187152309787580766 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Current Scenario and Future Prospect in the Management of COVID-19
Current Medicinal Chemistry Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design Turning Up the Pressure on Vascular Disease
Current Neurovascular Research Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety A Discussion of Natural Rubber Latex Allergy with Special Reference to Children: Clinical Considerations
Current Drug Targets - Immune, Endocrine & Metabolic Disorders An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies
Current Pharmaceutical Design Porphyromonas gingivalis Mediated Periodontal Disease and Atherosclerosis:Disparate Diseases with Commonalities in Pathogenesis Through TLRs
Current Pharmaceutical Design The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Current Drug Safety Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Bioavailability Enhancement of Poorly Soluble Drugs: The Holy Grail in Pharma Industry
Current Pharmaceutical Design Serum Tryptophan, Tryptophan Catabolites and Brain-derived Neurotrophic Factor in Subgroups of Youngsters with Autism Spectrum Disorders
CNS & Neurological Disorders - Drug Targets Echinocandins for the Nursery: An Update
Current Drug Metabolism Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research Gene Therapy for Pituitary Tumors
Current Gene Therapy The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for “New Use”
Recent Patents on Anti-Infective Drug Discovery